We are now developing stable peptides with a long half-life in vivo, based on amino acid sequence of RLYE, which are used to effectively inhibit VEGFR-2 function in vascular endothelial cells and thereby inhibit tumor angiogenesis, upon which solid tumors depend for growth and metastasis. This evidence concerns the gene KDR and neoplasm.